METHOD FOR DELIVERING PARTICULATE DRUGS TO TISSUES
    1.
    发明申请
    METHOD FOR DELIVERING PARTICULATE DRUGS TO TISSUES 审中-公开
    将颗粒药物递送给组织的方法

    公开(公告)号:WO2007124224A3

    公开(公告)日:2008-04-17

    申请号:PCT/US2007064679

    申请日:2007-03-22

    Abstract: The present invention is concerned with delivering a pharmaceutical composition to a tissue target of a mammalian subject for treating brain diseases or disorders. The process includes the steps of: (i) providing a dispersion of the pharmaceutical composition as particles having an average particle size of from about 150 nm to about 100 microns, and (ii) administering the dispersion to the mammalian subject for delivery to the tissue target of a portion of the pharmaceutical composition by cells capable of reaching the tissue target. The dispersion of the pharmaceutical composition as particles, for example, can be phagocytised or adsorbed by the cells prior or subsequent to administration into the mammalian subject. The dispersion of the pharmaceutical composition can be administered to the central nervous system or the vascular system. After administration, the loaded cells transport the pharmaceutical composition as particles into the tissue target.

    Abstract translation: 本发明涉及将药物组合物递送至哺乳动物受试者的组织靶以治疗脑部疾病或病症。 该方法包括以下步骤:(i)提供药物组合物的分散体作为平均粒度为约150nm至约100微米的颗粒,和(ii)向哺乳动物受试者施用分散体以递送至组织 通过能够到达组织靶的细胞的一部分药物组合物的靶标。 例如,作为颗粒的药物组合物的分散体可以在给予哺乳动物受试者之前或之后被细胞吞噬或吸附。 药物组合物的分散体可以施用于中枢神经系统或血管系统。 给药后,负载的细胞将药物组合物作为颗粒输送到组织靶中。

    EX-VIVO APPLICATION OF SOLID MICROPARTICULATE THERAPEUTIC AGENTS
    2.
    发明申请
    EX-VIVO APPLICATION OF SOLID MICROPARTICULATE THERAPEUTIC AGENTS 审中-公开
    固体微粒治疗药物的实例应用

    公开(公告)号:WO2005123907A3

    公开(公告)日:2007-08-23

    申请号:PCT/US2005022992

    申请日:2005-06-08

    Abstract: The present invention is concerned with a method of preparing and delivering small particles of a pharmaceutically active material to a mammalian subject for treating diseases or disorders. A preferred embodiment entails: (i) the collection of tissue cells from an animal donor, (ii) selective or non-selective growth of these cells in a cell culture medium to which is added solid particles of a therapeutically active compound, mostly free of a drug carrier (about 10% or less, by weight), and having an average particle size of less than about 100 microns, (iii) contacting the cells in the cell culture medium with the solid particles of therapeutically active compound causing the particles to be taken up by the cells into either the intracellular compartment of the cultured cells, attachment of the active compound as particles to the periphery of such cells, or a combination of intracellular uptake and attachment to the cell surface, (iv) optionally, isolation and/or resuspension of the cells prepared in steps i through iii, (v) administering the cells to the mammalian subject. The pharmaceutically active material can be administered intravenously, intramuscularly, subcutaneously, intradermally, intra-articularly, intrathecally, epidurally, intracerebrally, via buccal route, rectally, topically, transdermally, orally, intranasally, via pulmonary route, intraperitoneally, or combinations threof. After administration, the loaded cells transport the pharmaceutical composition as particles.

    Abstract translation: 本发明涉及制备和递送药物活性物质的小颗粒到哺乳动物受试者中用于治疗疾病或病症的方法。 优选的实施方案包括:(i)从动物供体收集组织细胞,(ii)这些细胞在细胞培养基中的选择性或非选择性生长,其中加入主要不含 药物载体(约10重量%或更少,重量百分比),平均粒径小于约100微米,(iii)使细胞培养基中的细胞与治疗活性化合物的固体颗粒接触, 被细胞吸收到培养细胞的细胞内隔室中,将活性化合物作为颗粒附着到这种细胞的周边,或细胞内摄取和附着到细胞表面的组合,(iv)任选的分离和 /或在步骤i至iii中制备的细胞的再悬浮,(v)向哺乳动物受试者施用细胞。 药物活性物质可以通过静脉内,肌肉内,皮下,皮内,关节内,鞘内,硬膜外,脑内,经口颊途径,直肠,局部,经皮,口服,鼻内,经由肺途径,腹膜内或组合Threof施用。 给药后,加载的细胞将药物组合物作为颗粒运输。

    7.
    发明专利
    未知

    公开(公告)号:BRPI0510271A

    公开(公告)日:2007-10-30

    申请号:BRPI0510271

    申请日:2005-06-08

    Abstract: The present invention is concerned with a method of preparing and delivering small particles of a pharmaceutically active material to a mammalian subject for treating diseases or disorders. A preferred embodiment entails: (i) the collection of tissue cells from an animal donor, (ii) selective or non-selective growth of these cells in a cell culture medium to which is added solid particles of a therapeutically active compound, mostly free of a drug carrier (about 10% or less, by weight), and having an average particle size of less than about 100 microns, (iii) contacting the cells in the cell culture medium with the solid particles of therapeutically active compound causing the particles to be taken up by the cells into either the intracellular compartment of the cultured cells, attachment of the active compound as particles to the periphery of such cells, or a combination of intracellular uptake and attachment to the cell surface, (iv) optionally, isolation and/or resuspension of the cells prepared in steps i through iii, (v) administering the cells to the mammalian subject. The pharmaceutically active material can be administered intravenously, intramuscularly, subcutaneously, intradermally, intra-articularly, intrathecally, epidurally, intracerebrally, via buccal route, rectally, topically, transdermally, orally, intranasally, via pulmonary route, intraperitoneally, or combinations thereof. After administration, the loaded cells transport the pharmaceutical composition as particles.

    9.
    发明专利
    未知

    公开(公告)号:NO20055616D0

    公开(公告)日:2005-11-28

    申请号:NO20055616

    申请日:2005-11-28

    Applicant: BAXTER INT

    Abstract: The present invention relates to compositions of submicron- to micron-size particles of antimicrobial agents. More particularly the invention relates to a composition of an antimicrobial agent that renders the agent potent against organisms normally considered to be resistant to the agent. The composition comprises an aqueous suspension of submicron-tomicron-size particles containing the agent coated with at least one surfactant selected from the group consisting of: ionic surfactants, non-ionic surfactants, biologically derived surfactants, and amino acids and their derivatives. The particles have a volume-weighted mean particle size of less than 5 µm as measured by laser diffractonetry.

Patent Agency Ranking